Global Neuropathy Pain Treatment Market 2017-2021 - Product Image

Global Neuropathy Pain Treatment Market 2017-2021

  • ID: 4143779
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Allodynic Therapeutics
  • Centrexion Therapeutics
  • Dr Reddy's Laboratories
  • Immune Pharmaceuticals
  • Newron Pharmaceuticals
  • Sienna Biopharmaceuticals
  • MORE
About Neuropathy Pain Treatment

Neuropathic pain is a complex, chronic pain condition that is accompanied by tissue injury. In neuropathic pain, the nerve fibers may be damaged, dysfunctional, or injured. These nerve fibers send incorrect signals to other pain centers. The impact of nerve fiber injury creates a change in nerve function at the site of injury and areas surrounding the injury.

The analysts forecast the global neuropathy pain treatment market to grow at a CAGR of 5.85% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global neuropathy pain treatment market for 2017-2021. To calculate the market size, the report considers the indications of neuropathic pain such as diabetic neuropathy, chemotherapy-induced neuropathy pain, postherpetic neuralgia, and others.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Neuropathy Pain Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Depomed
- Eli Lilly
- Endo International
- Pfizer

Other prominent vendors
- Allodynic Therapeutics
- Arbor Pharmaceuticals
- Astellas Pharma
- Aurobindo Pharma
- Avanir Pharmaceuticals
- Biogen
- CAPNIA
- Centrexion Therapeutics
- Cerecor
- ContraVir Pharmaceuticals
- Crescita Therapeutics
- DAEWOONG
- Daiichi Sankyo
- Dr. Reddy's Laboratories
- Eisai Pharmaceuticals
- Grünenthal
- GlaxoSmithKline
- Hydra Biosciences
- Immune Pharmaceuticals
- Jiangsu Hengrui Medicine
- Lexicon Pharmaceuticals
- Lupin
- Mallinckrodt
- Midatech Pharma
- Neurotune
- Newron Pharmaceuticals
- Novaremed
- Novartis
- PledPharma
- Premier Biomedical
- Regeneron
- Samyang Biopharmaceuticals
- Sienna Biopharmaceuticals
- Sun Pharma
- Teva Pharmaceutical Industries
- TheraVasc
- TORAY INDUSTRIES
- Torrent Pharmaceuticals
- UCB Pharma
- VanWorld Pharmaceutical (a subsidiary of Vanway)
- VistaGen Therapeutics
- WEX Pharmaceuticals
- WINSTON PHARMACEUTICALS
- Wockhardt
- Yuhan Corporation

Market drivers
- Focus toward the development of novel therapeutics for postherpetic neuralgia.
- For a full, detailed list, view the full report

Market challenges
- High unmet needs in the treatment of neuropathic pain affects the adoption rates.
- For a full, detailed list, view the full report

Market trends
- Increasing mergers and acquisitions would lead to further consolidation.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allodynic Therapeutics
  • Centrexion Therapeutics
  • Dr Reddy's Laboratories
  • Immune Pharmaceuticals
  • Newron Pharmaceuticals
  • Sienna Biopharmaceuticals
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: An overview of neuropathic pain

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Pipeline landscape

PART 08: Market segmentation by indication
  • Diabetic neuropathy
  • Chemotherapy-induced neuropathy pain
  • Postherpetic neuralgia
  • Others
PART 09: Market segmentation by drug class
  • Calcium channel alpha 2-delta ligands
  • Serotonin-norepinephrine reuptake inhibitors (SNRIs)
  • TCAs
  • Opioid analgesics
  • Others
PART 10: Geographical segmentation
  • Neuropathy pain treatment market in Americas
  • Neuropathy pain treatment market in EMEA
  • Neuropathy pain treatment market in APAC
PART 11: Decision framework

PART 12: Drivers and challenges
  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments
PART 13: Market trends
  • Development of topical patches for the treatment of neuropathic pain likely to change market dynamics
  • Growing focus on emerging economies
  • Increasing mergers and acquisitions would lead to further consolidation
PART 14: Vendor landscape
  • Competitive scenario
PART 15: Key vendor analysis
  • Depomed
  • Eli Lilly
  • Endo International
  • Pfizer
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Global neuropathy pain treatment market snapshot
Exhibit 02: Global neuropathic pain treatment market 2016-2021 ($ millions)
Exhibit 03: Opportunity analysis in global neuropathy pain treatment market
Exhibit 04: Five forces analysis
Exhibit 05: Key pipeline candidates by indication
Exhibit 06: Pipeline analysis
Exhibit 07: Global neuropathy pain treatment market segmentation by indication 2016
Exhibit 08: Global diabetic neuropathy market 2016-2021 ($ millions)
Exhibit 09: Global chemotherapy-induced neuropathic pain drugs market 2016-2021 ($ millions)
Exhibit 10: Global postherpetic neuralgia drugs market 2016-2021 ($ millions)
Exhibit 11: Global other neuropathy pain drugs market 2016-2021 ($ millions)
Exhibit 12: Neuropathy pain market by drug class 2016
Exhibit 13: Segmentation of global neuropathy pain treatment market based on geography 2016 and 2021
Exhibit 14: Neuropathy pain treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 15: Market scenario in Americas
Exhibit 16: Neuropathic pain treatment market in Americas 2016-2021 ($ millions)
Exhibit 17: Market scenario in EMEA
Exhibit 18: Neuropathy pain treatment market in EMEA 2016-2021 ($ millions)
Exhibit 19: Market scenario in APAC
Exhibit 20: Neuropathic pain treatment market in APAC 2016-2021 ($ millions)
Exhibit 21: Impact of drivers
Exhibit 22: Impact of challenges
Exhibit 23: Competitive structure analysis of global neuropathic pain treatment market 2016
Exhibit 24: Competitive analysis of global neuropathic pain treatment market
Exhibit 25: Strategic success factors of companies in global neuropathic pain treatment market
Exhibit 26: Depomed: Key highlights
Exhibit 27: Depomed: Strength assessment
Exhibit 28: Depomed: Strategy assessment
Exhibit 29: Depomed: Opportunity assessment
Exhibit 30: Eli Lilly: Key highlights
Exhibit 31: Eli Lilly: Strength assessment
Exhibit 32: Eli Lilly: Strategy assessment
Exhibit 33: Eli Lilly: Opportunity assessment
Exhibit 34: Eli Lilly: YoY and growth rate of Cymbalta 2013-2015 ($ millions)
Exhibit 35: Endo International: Key highlights
Exhibit 36: Endo International: Strength assessment
Exhibit 37: Endo International: Strategy assessment
Exhibit 38: Endo International: Opportunity assessment
Exhibit 39: Endo International: YoY and growth rate of LIDODERM (branded) 2013-2015 ($ millions)
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Exhibit 44: Pfizer: YoY and growth rate of LYRICA 2013-2015 ($ millions)
Exhibit 45: Pfizer: YoY and growth rate of NEURONTIN 2013-2015 ($ millions)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allodynic Therapeutics
  • Centrexion Therapeutics
  • Dr Reddy's Laboratories
  • Immune Pharmaceuticals
  • Newron Pharmaceuticals
  • Sienna Biopharmaceuticals
  • MORE
New Report Released: – Global Neuropathy Pain Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global neuropathy pain treatment market: Depomed, Eli Lilly, Endo International, and Pfizer.

Other Prominent Vendors in the market are: Allodynic Therapeutics, Arbor Pharmaceuticals, Astellas Pharma, Aurobindo Pharma, Avanir Pharmaceuticals, Biogen, CAPNIA, Centrexion Therapeutics, Cerecor, ContraVir Pharmaceuticals, Crescita Therapeutics, DAEWOONG, Daiichi Sankyo, Dr. Reddy's Laboratories, Eisai Pharmaceuticals, Grünenthal, GlaxoSmithKline, Hydra Biosciences, Immune Pharmaceuticals, Jiangsu Hengrui Medicine, Lexicon Pharmaceuticals, Lupin, Mallinckrodt, Midatech Pharma, Neurotune, Newron Pharmaceuticals, Novaremed, Novartis, PledPharma, Premier Biomedical, Regeneron, Samyang Biopharmaceuticals, Sienna Biopharmaceuticals, Sun Pharma, Teva Pharmaceutical Industries, TheraVasc, TORAY INDUSTRIES, Torrent Pharmaceuticals, UCB Pharma, VanWorld Pharmaceutical (a subsidiary of Vanway), VistaGen Therapeutics, WEX Pharmaceuticals, WINSTON PHARMACEUTICALS, Wockhardt, and Yuhan Corporation.

Commenting on the report, an analyst from the research team said: “One trend in market is growing focus on emerging economies. The increasing focus of research institutes and vendors to tap the potential treatments in emerging economies will likely bring substantial growth opportunities. The increasing incidence of individuals with pain has fueled the demand in regions such as China, India, and Brazil. In addition, the research institutes have issued guidelines to address the unmet needs in the treatment of pain. For instance, a group of pain specialists from across APAC stated to have tailored guidelines for each region for the treatment of neuropathic pain. They also started to put greater effort to communicate about neuropathic pain treatments with general physicians. This will increase the accessibility of drugs in emerging and low- and middle-income regions of APAC. Vendors are also looking to tap the potential in emerging economies. For instance, Daiichi Sankyo, Yuhan Corporation, Eisai Pharmaceuticals, and Jiangsu Hengrui Medicine are some of the companies that are increasingly conducting R&D activities to develop effective treatments in APAC. For instance, in December 2016, Yuhan Corporation planned a Phase III trial for evaluating YHD1119 for the treatment of neuropathic pain in South Korea. Daiichi Sankyo is also looking to penetrate into the market with mirogabalin, which is being evaluated for three different indications such as fibromyalgia, diabetic peripheral neuropathic pain, and postherpetic neuralgia.”

According to the report, one driver in market is presence of large patient pool. The presence of large patient pool with neuropathic pain is expected to fuel the market growth. Neuropathic pain is associated with various disorders such as diabetic neuropathy, chemotherapy-induced pain, shingles, and herniated disk. There has been growing cases of the population with these disorders. For instance, according to the CDC 2014 statistics, 29.1 million individuals in the US have diabetes in 2014. Out of this, around 6-7 individuals per 1,000 individuals are suffering from diabetic neuropathy. Also, the increasing individuals preferring chemotherapy for cancer treatment is fueling the cases of chemotherapy-induced pain. For instance, according to the CDC, about 650,000 individuals with cancer receive chemotherapy in outpatient oncology clinics in the US. In addition, the increasing incidence of shingles is expected to drive the market growth. According to the CDC, the incidence of shingles is approximately four per 1,000 US population annually. Further, the disease is more prevalent in ages 60 and above. The incidence among individuals 60 years of age and above is 10 cases per 1,000 US population annually. Overall, there are an estimated one million cases of herpes zoster in the US annually. Such scenario will lead to an increase in adoption of neuropathic pain drugs, which will, in turn, drive the market growth.

Further, the report states that one challenge in market is patent expiries hamper the growth prospects. The patent expiry of major approved drugs is expected to impact the market adversely and is anticipated to slow down its growth during the forecast period. Patent expiry of a drug often results in the loss of an exclusive market for that drug, leading to a rapid decline in sales. For instance, Eli Lilly's Cymbalta lost its US patent protection in December 2013, allowing the US FDA to approve its generic versions for market use. Cymbalta lost its data package protection in European countries in 2014. Pfizer's LYRICA for neuropathic pain is set to expire in 2017 and will fuel the launch of generics after this period. Already for other indications, Consilient Health, a manufacturer of generic and specialty pharma products launched Rewisca (a generic version of LYRICA) with a cost less than 25% than branded LYRICA. Although the companies cannot market generic version for LYRICA before the expiry period, they may infringe the patent. This will have an adverse effect on the sales of LYRICA. In addition, many other companies are looking to launch the generic version of LYRICA for the treatment of neuropathic pain. This scenario is expected to affect the market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Depomed
  • Eli Lilly
  • Endo International
  • Pfizer
  • Allodynic Therapeutics
  • Arbor Pharmaceuticals
  • Astellas Pharma
  • Aurobindo Pharma
  • Avanir Pharmaceuticals
  • Biogen
  • CAPNIA
  • Centrexion Therapeutics
  • Cerecor
  • ContraVir Pharmaceuticals
  • Crescita Therapeutics
  • DAEWOONG
  • Daiichi Sankyo
  • Dr Reddy's Laboratories
  • Eisai Pharmaceuticals
  • Grünenthal
  • GlaxoSmithKline
  • Hydra Biosciences
  • Immune Pharmaceuticals
  • Jiangsu Hengrui Medicine
  • Lexicon Pharmaceuticals
  • Lupin
  • Mallinckrodt
  • Midatech Pharma
  • Neurotune
  • Newron Pharmaceuticals
  • Novaremed
  • Novartis
  • PledPharma
  • Premier Biomedical
  • Regeneron
  • Samyang Biopharmaceuticals
  • Sienna Biopharmaceuticals
  • Sun Pharma
  • Teva Pharmaceutical Industries
  • TheraVasc
  • TORAY INDUSTRIES
  • Torrent Pharmaceuticals
  • UCB Pharma
  • VanWorld Pharmaceutical (a subsidiary of Vanway)
  • VistaGen Therapeutics
  • WEX Pharmaceuticals
  • WINSTON PHARMACEUTICALS
  • Wockhardt
  • Yuhan Corporation
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll